{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:40:00Z","timestamp":1697334000606},"reference-count":12,"publisher":"Wiley","issue":"6-7","license":[{"start":{"date-parts":[[2008,1,21]],"date-time":"2008-01-21T00:00:00Z","timestamp":1200873600000},"content-version":"vor","delay-in-days":6443,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[1990,6]]},"abstract":"<jats:p><jats:bold>ABSTRACT. <\/jats:bold> The immunogenicity and safety of recombinant yeast\u2010derived hepatitis B vaccine given in doses of 0.6 \u03bcg, 1.25 \u03bcg, 2.5 \u03bcg and 5.0 \u03bcg were studied in 4 comparable groups of children aged 1\u201312 years. All children received three doses of vaccine at time 0, 1 month and 5 months. Immunogenicity appeared to be satisfactory in all 4 groups of children. In the early phase of the study, a dose\u2010response relationship was observed but there was no significant difference in the geometric mean titre among all 4 groups for any period studied. Antibody levels peaked at 9 months, declining thereafter. The geometric mean titre one year after the first vaccine dose was not significantly lower than that at the peak (9 months) in any individual group studied. The second year geometric mean titre was similar in all 4 groups and lower than that of the first year. Sero\u2010conversion with antibody titres &gt; 10 mIU\/ml was 100% in the 5.0 \u03bcg group and &gt; 90% in the other 3 groups. There were no adverse reactions of any significance. The immunogenicity of recombinant yeast\u2010derived hepatitis B vaccine was found to be adequate even at as low a dosage as 0.6 \u03bcg when administered in a 3\u2010dose regimen.<\/jats:p>","DOI":"10.1111\/j.1651-2227.1990.tb11522.x","type":"journal-article","created":{"date-parts":[[2008,1,21]],"date-time":"2008-01-21T18:34:16Z","timestamp":1200940456000},"page":"593-598","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and Safety of Low Doses of Recombinant Yeast\u2010Derived Hepatitis B Vaccine"],"prefix":"10.1111","volume":"79","author":[{"given":"K. L.","family":"TAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"OON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. T.","family":"GOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Y. M.","family":"WONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,21]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90796-0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1972.tb03982.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/14.1.173"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(86)91223-5"},{"key":"e_1_2_1_6_2","first-page":"308","article-title":"Hepatitis B vaccination\u2010A Singapore experience","volume":"30","author":"Oon CJ.","year":"1986","journal-title":"Acta Med Nagasaki"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6544.404"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.1984.03340450028021","article-title":"Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA","volume":"251","author":"Scolnick EM","year":"1984","journal-title":"JAMA"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890170109"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92740-5"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.1.156"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(86)92668-X"},{"key":"e_1_2_1_13_2","first-page":"509","volume-title":"Viral hepatitis 1981. International Symposium","author":"Gondeau A","year":"1983"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1651-2227.1990.tb11522.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1651-2227.1990.tb11522.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:16:34Z","timestamp":1693480594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1651-2227.1990.tb11522.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,6]]},"references-count":12,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[1990,6]]}},"alternative-id":["10.1111\/j.1651-2227.1990.tb11522.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1651-2227.1990.tb11522.x","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"value":"0803-5253","type":"print"},{"value":"1651-2227","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,6]]},"assertion":[{"value":"2008-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}